These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 26614823)

  • 1. A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve.
    Bairey Merz CN; Handberg EM; Shufelt CL; Mehta PK; Minissian MB; Wei J; Thomson LE; Berman DS; Shaw LJ; Petersen JW; Brown GH; Anderson RD; Shuster JJ; Cook-Wiens G; Rogatko A; Pepine CJ
    Eur Heart J; 2016 May; 37(19):1504-13. PubMed ID: 26614823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late sodium channel blockade improves angina and myocardial perfusion in patients with severe coronary microvascular dysfunction: Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction ancillary study.
    Rambarat CA; Elgendy IY; Handberg EM; Bairey Merz CN; Wei J; Minissian MB; Nelson MD; Thomson LEJ; Berman DS; Shaw LJ; Cook-Wiens G; Pepine CJ
    Int J Cardiol; 2019 Feb; 276():8-13. PubMed ID: 30293664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease.
    Mehta PK; Goykhman P; Thomson LE; Shufelt C; Wei J; Yang Y; Gill E; Minissian M; Shaw LJ; Slomka PJ; Slivka M; Berman DS; Bairey Merz CN
    JACC Cardiovasc Imaging; 2011 May; 4(5):514-22. PubMed ID: 21565740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis: The MARINA Randomized, Double-Blinded, Controlled Pilot Trial.
    Koh JS; Hung OY; Eshtehardi P; Kumar A; Rabah R; Raad M; Kumar S; Chaudhry S; Gupta S; Hosseini H; Brilakis E; Corban M; Sabbak N; Burnett GM; Liu C; Mehta PK; Quyyumi AA; Samady H
    Circ Cardiovasc Interv; 2020 Dec; 13(12):e008204. PubMed ID: 33272036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the Antianginal Drugs Ranolazine, Nicorandil, and Ivabradine on Coronary Microvascular Function in Patients With Nonobstructive Coronary Artery Disease: A Meta-analysis of Randomized Controlled Trials.
    Zhu H; Xu X; Fang X; Zheng J; Zhao Q; Chen T; Huang J
    Clin Ther; 2019 Oct; 41(10):2137-2152.e12. PubMed ID: 31548105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daily Activity Measured With Wearable Technology as a Novel Measurement of Treatment Effect in Patients With Coronary Microvascular Dysfunction: Substudy of a Randomized Controlled Crossover Trial.
    Birkeland K; Khandwalla RM; Kedan I; Shufelt CL; Mehta PK; Minissian MB; Wei J; Handberg EM; Thomson LE; Berman DS; Petersen JW; Anderson RD; Cook-Wiens G; Pepine CJ; Bairey Merz CN
    JMIR Res Protoc; 2017 Dec; 6(12):e255. PubMed ID: 29263019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ranolazine on noninvasive coronary flow reserve in patients with myocardial ischemia but without obstructive coronary artery disease.
    Tagliamonte E; Rigo F; Cirillo T; Astarita C; Quaranta G; Marinelli U; Caruso A; Romano C; Capuano N
    Echocardiography; 2015 Mar; 32(3):516-21. PubMed ID: 25041234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myocardial tissue deformation is reduced in subjects with coronary microvascular dysfunction but not rescued by treatment with ranolazine.
    Nelson MD; Sharif B; Shaw JL; Cook-Wiens G; Wei J; Shufelt C; Mehta PK; Thomson LEJ; Berman DS; Thompson RB; Handberg EM; Pepine CJ; Li D; Bairey Merz CN
    Clin Cardiol; 2017 May; 40(5):300-306. PubMed ID: 28004395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporal Trends in Angina, Myocardial Perfusion, and Left Ventricular Remodeling in Women With No Obstructive Coronary Artery Disease Over 1-Year Follow-Up: Results From WISE-CVD.
    Quesada O; Hermel M; Suppogu N; Aldiwani H; Shufelt C; Mehta PK; Cook-Wiens G; Maughan J; Berman DS; Thomson LEJ; Handberg EM; Pepine CJ; Bairey Merz CN; Wei J
    J Am Heart Assoc; 2020 Jul; 9(13):e016305. PubMed ID: 32578481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ranolazine in Symptomatic Diabetic Patients Without Obstructive Coronary Artery Disease: Impact on Microvascular and Diastolic Function.
    Shah NR; Cheezum MK; Veeranna V; Horgan SJ; Taqueti VR; Murthy VL; Foster C; Hainer J; Daniels KM; Rivero J; Shah AM; Stone PH; Morrow DA; Steigner ML; Dorbala S; Blankstein R; Di Carli MF
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28473401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Typical angina is associated with greater coronary endothelial dysfunction but not abnormal vasodilatory reserve.
    AlBadri A; Leong D; Bairey Merz CN; Wei J; Handberg EM; Shufelt CL; Mehta PK; Nelson MD; Thomson LE; Berman DS; Shaw LJ; Cook-Wiens G; Pepine CJ
    Clin Cardiol; 2017 Oct; 40(10):886-891. PubMed ID: 28605043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of ranolazine on left ventricular diastolic and systolic function in patients with chronic coronary disease and stable angina.
    Babalis D; Tritakis V; Floros G; Mouzarou A; Kafkas N; Bampali K; Mertzanos G
    Hellenic J Cardiol; 2015; 56(3):237-41. PubMed ID: 26021246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial.
    Alexander KP; Weisz G; Prather K; James S; Mark DB; Anstrom KJ; Davidson-Ray L; Witkowski A; Mulkay AJ; Osmukhina A; Farzaneh-Far R; Ben-Yehuda O; Stone GW; Ohman EM
    Circulation; 2016 Jan; 133(1):39-47. PubMed ID: 26555329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angina relates to coronary flow in women with ischemia and no obstructive coronary artery disease.
    Suppogu N; Wei J; Quesada O; Shufelt C; Cook-Wiens G; Samuels B; Petersen JW; Anderson RD; Handberg EM; Pepine CJ; Bairey Merz CN
    Int J Cardiol; 2021 Jun; 333():35-39. PubMed ID: 33662486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac magnetic resonance myocardial perfusion reserve index is reduced in women with coronary microvascular dysfunction. A National Heart, Lung, and Blood Institute-sponsored study from the Women's Ischemia Syndrome Evaluation.
    Thomson LE; Wei J; Agarwal M; Haft-Baradaran A; Shufelt C; Mehta PK; Gill EB; Johnson BD; Kenkre T; Handberg EM; Li D; Sharif B; Berman DS; Petersen JW; Pepine CJ; Bairey Merz CN
    Circ Cardiovasc Imaging; 2015 Apr; 8(4):. PubMed ID: 25801710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ranolazine and Microvascular Angina by PET in the Emergency Department: Results From a Pilot Randomized Controlled Trial.
    Safdar B; D'Onofrio G; Dziura J; Russell RR; Johnson C; Sinusas AJ
    Clin Ther; 2017 Jan; 39(1):55-63. PubMed ID: 28081848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ranolazine for improving coronary microvascular function in patients with nonobstructive coronary artery disease: a systematic review and meta-analysis with a trial sequential analysis of randomized controlled trials.
    Ling H; Fu S; Xu M; Wang B; Li B; Li Y; Liu X; Zhang X; Wang Q; Li A; Liu M
    Quant Imaging Med Surg; 2024 Feb; 14(2):1451-1465. PubMed ID: 38415135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Ranolazine for Treatment of Coronary Microvascular Dysfunction-A Systematic Review and Meta-analysis of Randomized Trials.
    Kofler T; Hess S; Moccetti F; Pepine CJ; Attinger A; Wolfrum M; Toggweiler S; Kobza R; Cuculi F; Bossard M
    CJC Open; 2021 Jan; 3(1):101-108. PubMed ID: 33458636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis of Microvascular Angina Using Cardiac Magnetic Resonance.
    Liu A; Wijesurendra RS; Liu JM; Forfar JC; Channon KM; Jerosch-Herold M; Piechnik SK; Neubauer S; Kharbanda RK; Ferreira VM
    J Am Coll Cardiol; 2018 Mar; 71(9):969-979. PubMed ID: 29495996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ChaMP-CMD: A Phenotype-Blinded, Randomized Controlled, Cross-Over Trial.
    Sinha A; Rahman H; Douiri A; Demir OM; De Silva K; Clapp B; Webb I; Gulati A; Pinho P; Dutta U; Ellis H; Shah AM; Chiribiri A; Marber M; Webb AJ; Perera D
    Circulation; 2024 Jan; 149(1):36-47. PubMed ID: 37905403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.